Common pills tested to fight silent liver damage
NCT ID NCT07338331
Summary
This study tested whether daily low-dose aspirin or the diabetes drug empagliflozin (an SGLT2 inhibitor) could improve liver health in people with type 2 diabetes and fatty liver disease. For six months, 80 participants took one of these medications. Researchers measured changes in liver enzymes, cholesterol, and liver stiffness to see which treatment might better control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculty of Pharmacy
Banī Suwayf, Beni Suweif Governorate, 0000, Egypt
Conditions
Explore the condition pages connected to this study.